Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): wherein R 1 , R 2 , and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.
1. A compound, of Formula (I):
wherein:
R 1 is chosen from aryl and heteroaryl, and may be optionally substituted with one R 3 substituent;
R 2 is chosen from aryl or heteroaryl, and may be optionally substituted with one or more R 4 substituents;
R 3 is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , cyano, —C(O)N(R 6 ) 2 , —C(O)C 1-4 alkyl, haloalkyl, oxo, and halo;
each R 4 is independently chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, —OC 1-6 cycloalkyl, —OC 1-6 heterocycloalkyl, aryl, heteroaryl, haloalkyl, haloalkoxy, halo, —NR 5 R 6 , —(CH 2 ) m CR 7 ═CR 9 C(O)Me, —(CH 2 ) m CR 7 ═CR 9 C(O)NR 7 2 , —(CH 2 ) m CR 7 ═CR 9 CN, and wherein if R 1 is indolyl then R 4 cannot be hydrogen;
R 5 is chosen from hydrogen, cyano, —C(O)CF 3 , —C(O)CH═CH 2 , —C(O)CR 7 ═CH 2 , —C(O)CH═CHR 7 , —C(O)CR 7 ═CHR 7 , —C(O)CH═CR 7 2 , —C(O)CH═CHCH 2 R 8 , —C(O)CH═CHC(O)CH 2 R 8 , —COC(CN)═CHR 6 , —C(O)(C(O)NH 2 )═CHR 6 , —S(O) 2 CH═CH 2 , —(CH 2 ) m CR 7 ═CR 9 C(O)Me, —(CH 2 ) m CR 7 ═CR 9 C(O)NR 7 2 , —(CH 2 ) m CR 7 ═CR 9 CN, and wherein if R 5 is —C(O)CH═CHR 7 then R 1 must have a R 3 substituent;
R 6 is chosen from hydrogen, —C 1-4 alkyl, and —(CH 2 ) n C 3-7 cycloalkyl;
each R 7 is independently chosen from hydrogen, —CN, —C 1-4 alkyl, —C 3-7 cycloalkyl, —C 3-7 heterocycle, aryl, and heteroaryl where aryl and heteroaryl may be optionally substituted with one or more R 9 ;
R 8 is chosen from hydrogen, —C 1-4 alkyl, —C 1-4 alkylaryl, —C 1-4 alkylheteroaryl, —C 3-7 cycloalkyl, —C 3-7 heterocycle, —OH, —OC 1-4 alkyl, —C 1-4 alkylOC 1-4 alkyl, —NH 2 , —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , heterocycle, aryl and heteroaryl;
R 9 is chosen from hydrogen, —C 1-4 alkyl, —CN, —CF 3 , —C(O)Me, —C(O)NH 2 , and aryl;
R 10 is chosen from H and —C 1-4 alkyl;
R 11 is chosen from hydrogen and —C 1-4 alkyl, optionally substituted with —OPO(OR 12 ) 2 , —OC(O)R 13 , or an amino acid;
R 12 is chosen from hydrogen and —C 1-6 alkyl;
R 13 is —C 1-6 alkyl;
m is chosen from 1, 2 and 3;
n is chosen from 0, 1, 2, and 3; and
wherein the compound is not
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
2. The compound of claim 1 , wherein the compound has structural Formula (II):
wherein:
R 1 is chosen from aryl and heteroaryl, and may be optionally substituted with one R 3 substituent;
X is chosen from CR 4b and N;
R 3 is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , cyano, —C(O)N(R 6 ) 2 , —C(O)C 1-4 alkyl, haloalkyl, oxo, and halo;
R 4b is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, aryl, heteroaryl, haloalkyl, haloalkoxy, and halo;
R 4c is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, —OC 1-6 cycloalkyl, and —OC 1-6 heterocycloalkyl;
R 6 is chosen from hydrogen and —C 1-4 alkyl;
R 11 is chosen from hydrogen and —C 1-4 alkyl, optionally substituted with —OPO(OR 12 ) 2 , —OC(O)R 13 , or an amino acid; and
R 12 is chosen from hydrogen and —C 1-6 alkyl;
R 13 is —C 1-6 alkyl.
3. The compound of claim 2 , wherein
R 1 is phenyl, optionally substituted with one R 3 substituent; and
R 3 is chosen from hydrogen, cyano, —OC 1-4 alkyl, and halo.
4. The compound of claim 2 , wherein
R 1 is heteroaryl, and may be optionally substituted with one R 3 substituent; and R 3 is chosen from hydrogen, cyano, —OC 1-4 alkyl, and halo.
5. The compound of claim 4 , wherein R 1 is pyridyl.
6. The compound of claim 2 , wherein:
R 4b is chosen from hydrogen, —C 1-4 alkyl, heteroaryl, —OC 1-4 alkyl, haloalkyl, haloalkoxy,and halo.
7. The compound of claim 2 , wherein R 4c is hydrogen.
8. The compound of claim 1 , wherein the compound has structural Formula (III):
wherein:
R 1 is chosen from aryl and heteroaryl, and is substituted with one R 3 substituent;
X is chosen from CR 4b and N;
R 3 is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, —NHC 1-4 alkyl, —N(C 1-4 alkyl) 2 , cyano, —C(O)N(R 6 ) 2 , —C(O)C 1-4 alkyl, haloalkyl, oxo, and halo;
R 4b is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, aryl, heteroaryl, haloalkyl, haloalkoxy, halo, and wherein if R 1 is indolyl then R 4b cannot be hydrogen;
R 4c is chosen from hydrogen, —C 1-4 alkyl, —OC 1-4 alkyl, —OC 1-6 cycloalkyl, and —OC 1-6 heterocycloalkyl;
R 6 is chosen from hydrogen and —C 1-4 alkyl;
R 11 is chosen from hydrogen and —C 1-4 alkyl, optionally substituted with —OPO(OR 12 ) 2 , —OC(O)R 13 , or an amino acid;
R 12 is chosen from hydrogen and —C 1-6 alkyl;
R 13 is —C 1-6 alkyl; and
wherein the compound is not
9. The compound of claim 8 , wherein
R 1 is phenyl, optionally substituted with one R 3 substituent; and
R 3 is chosen from hydrogen, cyano, —OC 1-4 alkyl, and halo.
10. The compound of claim 8 , wherein
R 1 is heteroaryl, and may be optionally substituted with one R 3 substituent; and
R 3 is chosen from hydrogen, cyano, —OC 1-4 alkyl, and halo.
11. The compound of claim 10 , wherein R 1 is pyridyl.
12. The compound of claim 8 , wherein:
R 4b is chosen from hydrogen, —C 1-4 alkyl, heteroaryl, —OC 1-4 alkyl, haloalkyl, haloalkoxy, and halo.
13. The compound of claim 8 , wherein R 4c is hydrogen.
14. The compound of claim 1 , wherein the compound has structural Formula (IV):
wherein:
Y is chosen from CH and N;
R 41 is chosen from —C 1-4 alkyl, —OC 1-4 alkyl, cyano, and halo;
R 42 is chosen from hydrogen and —OC 1-4 alkyl; and
R 43 is chosen from hydrogen and halo.
15. The compound of claim 1 , wherein the compound has structural Formula (V):
wherein:
Y is chosen from CH and N;
R 51 is chosen from —C 1-4 alkyl, —OC 1-4 alkyl, cyano, and halo;
R 52 is chosen from hydrogen and —OC 1-4 alkyl; and
R 53 is chosen from hydrogen and halo.
16. The compound of claim 1 , wherein the compound has structural Formula (VI):
wherein:
Y is chosen from CH and N; and
R 61 is chosen from —OC 1-4 alkyl, cyano, and halo.
17. The compound of claim 1 , wherein the compound has structural Formula (VII):
wherein:
Y is chosen from CH and N; and
R 71 is chosen from —OC 1-4 alkyl, cyano, and halo.
18. The compound of claim 1 , wherein the compound has structural Formula (VIII):
wherein:
Y is chosen from CH and N; and
R 81 is chosen from —OC 1-4 alkyl, cyano, and halo.
19. The compound of claim 1 , wherein the compound has structural Formula (IX):
wherein:
Y is chosen from CH and N; and
R 91 is chosen from —OC 1-4 alkyl, cyano, and halo.
20. The compound of claim 1 , wherein the compound is selected from
a pharmaceutically acceptable salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
21. The compound of claim 14 , wherein the compound is selected from
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (eg., tritium, deuterium), or a combination thereof.
22. The compound of claim 15 , wherein the compound is selected from
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
23. The compound of claim 16 , wherein the compound is selected from
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
24. The compound of claim 17 , wherein the compound is selected from
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
25. The compound of claim 18 , wherein the compound is selected from
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
26. The compound of claim 19 , wherein the compound is selected from
a salt thereof, an ester thereof, a free acid form thereof, a free base form thereof, a solvate thereof, a deuterated derivative thereof, a hydrate thereof, an N-oxide thereof, a clathrate thereof, a prodrug thereof, a polymorph thereof, a stereoisomer thereof, a geometric isomer thereof, a tautomer thereof, a mixture of tautomers thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a mixture of stereoisomers thereof, an isotope thereof (e.g., tritium, deuterium), or a combination thereof.
27. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle.